CIPLA1,374.00

Cipla Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSUNPHARMADRREDDYLUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹1.11L Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations6,678.26,603.86,163.26,693.97,051.07,073.06,729.76,957.57,589.47,074.56,541.27,119.3
Other Income176.3184.6249.3160.2190.6221.6289.5258.6269.0206.3148.2210.9
Total Income6,854.56,788.46,412.66,854.17,241.67,294.67,019.27,216.07,858.47,280.86,689.47,330.2
Expenses
+ Cost of Materials Consumed1,472.71,196.21,252.71,240.91,474.01,296.71,397.91,469.41,528.21,462.01,382.21,356.9
+ Purchases of Stock-in-Trade890.2927.2739.01,100.0814.6913.21,023.71,025.0893.01,248.61,284.71,251.7
+ Changes in Inventories-49.896.158.5-148.0-5.654.1-232.6-323.776.5-78.5-418.258.6
+ Employee Benefit Expense1,091.11,068.11,084.21,194.21,207.91,197.61,233.11,312.31,314.81,325.01,414.31,497.4
+ Finance Costs25.830.117.618.015.414.614.014.113.214.013.117.0
+ Depreciation & Amortisation290.0233.4288.3246.7271.7279.8308.7252.7297.0278.4382.9304.2
+ Other Expenses1,540.21,568.61,713.01,591.01,674.51,622.41,770.01,696.31,882.31,862.41,923.31,762.4
Total Expenses5,260.25,119.85,153.35,242.85,452.65,378.55,514.95,446.16,004.96,111.85,982.36,248.3
EBITDA1,733.81,747.51,315.91,715.81,885.61,988.91,537.61,778.11,894.81,255.1955.01,192.3
EBIT1,443.71,514.11,027.51,469.11,613.91,709.11,228.91,525.41,597.8976.7572.0888.1
Profit
PBT before Exceptional Items1,594.21,668.61,259.31,611.41,789.11,916.11,504.31,769.91,853.51,169.0707.11,081.9
+ Exceptional Items0.0-194.80.00.00.00.00.00.00.0-275.90.00.0
Pretax Income1,594.21,473.81,259.31,611.41,789.11,916.11,504.31,769.91,853.5893.1707.11,081.9
+ Current Tax456.8329.7511.1431.3459.0337.7480.4529.6468.4160.8282.2392.8
+ Deferred Tax-18.475.6-186.33.824.0-5.3-201.1-51.732.157.7-125.2-98.0
Tax Expense438.4405.3324.9435.1483.0332.4279.3477.9500.5218.6157.0294.8
+ Share of Associates & JVs-0.5-0.1-2.5-0.8-1.0-9.1-10.9-0.40.3-0.3-7.6-1.6
Net Income1,155.41,068.4931.91,175.51,305.01,574.61,214.11,291.61,353.4674.3542.5785.6
+ Net Income — Continuing Ops1,155.81,068.5934.41,176.31,306.01,583.71,225.01,292.11,353.1674.6550.1787.1
+ Other Comprehensive Income64.32.4-79.570.7131.2-37.754.581.4266.4204.1135.8194.1
Total Comprehensive Income1,219.61,070.8852.41,246.21,436.21,536.91,268.61,373.01,619.8878.4678.3979.6
Net Income to Common1,130.91,055.9939.01,177.61,302.51,570.51,221.81,297.61,351.2675.8554.6789.1
Minority Interest24.512.5-7.2-2.22.54.1-7.7-6.02.2-1.6-12.1-3.5
Per Share
Basic EPS14.0113.0811.6314.5816.1319.4515.1316.0716.738.376.879.77
Diluted EPS14.0013.0711.6214.5716.1219.4315.1216.0616.728.366.869.76
Other Comprehensive Income — detail
+ Other Comprehensive Income54.581.4266.4204.1135.8194.1
+ Items NOT to be Reclassified to P&L-15.9-1.5-52.7-6.2-6.0-1.6-52.3-8.5-0.0-2.4-178.024.3
+ Tax on Items NOT to be Reclassified-6.5-2.2-0.0-0.60.76.1
+ Tax on Items NOT to be Reclassified — alt tag-4.7-0.4-18.0-1.5-1.5-0.4
+ Items to be Reclassified to P&L65.82.5-43.372.4122.5-31.8113.086.1236.4203.7302.0188.7
+ Tax on Items to be Reclassified12.8-1.7-30.0-2.3-12.512.8
+ Tax on Items to be Reclassified — alt tag-9.7-1.11.5-3.1-13.24.7
Comprehensive Income — Owners of Parent1,197.91,057.0860.01,248.61,433.01,533.21,274.81,378.81,617.4879.7692.1982.6
Comprehensive Income — Non-controlling Interests21.713.8-7.7-2.43.23.7-6.2-5.82.4-1.3-13.8-3.0
Per Share — as-filed variants
Basic EPS — Continuing Operations14.0113.0811.6314.5816.1319.4515.1316.0716.738.376.879.77
Diluted EPS — Continuing Operations14.0013.0711.6214.5716.1219.4315.1216.0616.728.366.869.76
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit4,365.14,384.34,113.14,501.14,768.04,808.94,540.74,786.85,091.84,442.44,292.54,452.1
Gross Margin %65.3666.3966.7467.2467.6267.9967.4768.8067.0962.7965.6262.54
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)1,594.21,668.61,259.31,611.41,789.11,916.11,504.31,769.91,853.51,169.0707.11,081.9
− Exceptional Items (reconciliation)0.0-194.80.00.00.00.00.00.00.0-275.90.00.0
Net Income Adj (tax-effected)1,155.41,209.7931.91,175.51,305.01,574.61,214.11,291.61,353.4882.6542.5785.6
EPS Adj14.0114.8111.6314.5816.1319.4515.1316.0716.7310.966.879.77
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.002.002.002.002.002.002.002.002.00
Paid Up Equity Capital161.5161.5161.5161.5161.5161.5161.5161.6161.6161.6161.6161.6
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.